has been cited by the following article(s):
|
[1]
|
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
Journal of Neuro-Oncology,
2024
DOI:10.1007/s11060-023-04513-1
|
|
|
|
|
[2]
|
Temozolomide based treatment in glioblastoma: 6 vs. 12 months
Oncology Letters,
2024
DOI:10.3892/ol.2024.14551
|
|
|
|
|
[3]
|
Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis
Neuro-Oncology Practice,
2022
DOI:10.1093/nop/npac036
|
|
|
|
|
[4]
|
A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
Frontiers in Oncology,
2021
DOI:10.3389/fonc.2021.779491
|
|
|
|
|
[5]
|
The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
Oncology Reviews,
2020
DOI:10.4081/oncol.2020.461
|
|
|
|
|
[6]
|
Re-inventing the randomized controlled trial in medical oncology: The registry-based trial
Asia-Pacific Journal of Clinical Oncology,
2018
DOI:10.1111/ajco.12992
|
|
|
|
|
[7]
|
Re‐inventing the randomized controlled trial in medical oncology: The registry‐based trial
Asia-Pacific Journal of Clinical Oncology,
2018
DOI:10.1111/ajco.12992
|
|
|
|